B
lood pressure (BP) is determined by genetic factors, environmental factors, and their interactions. Genome-wide association studies have identified many genetic loci that are robustly associated with BP. [1] [2] [3] [4] [5] However, these findings together only explain a small proportion of the interindividual variation of BP. 6 A large number of genetic loci are yet to be identified. 6 It has been proposed that exploring the interaction between genes and environmental risk factors for BP may help to identify novel genetic loci underlying BP regulation. [7] [8] [9] In addition, gene-based analysis methods testing the joint contributions of single single nucleotide polymorphisms (SNPs) with modest effect may have higher power to detect BP loci.
Background-Gene-environmental interaction analysis can identify novel genetic factors for blood pressure (BP). We performed genome-wide analyses to identify genomic loci that interact with potassium to influence BP using single-marker (1 and 2 df joint tests) and gene-based tests among Chinese participants of the GenSalt study (Genetic Epidemiology Network of Salt Sensitivity). Methods and Results-Among 1876 GenSalt participants, the average of 3 urine samples was used to estimate potassium excretion. Nine BP measurements were taken using a random-zero sphygmomanometer. A total of 2.2 million single nucleotide polymorphisms were imputed using Affymetrix 6.0 genotype data and the Chinese Han of Beijing and Japanese of Tokyo HapMap reference panel. Promising findings (P<1.00×10 −4 ) from GenSalt were evaluated for replication among 775 Chinese participants of the MESA (Multi-ethnic Study of Atherosclerosis). Single nucleotide polymorphism and genebased results were meta-analyzed across the GenSalt and MESA studies to determine genome-wide significance. The 1 df tests identified interactions for ARL15 rs16882447 on systolic BP (P=2.83×10 −9 ) and RANBP3L rs958929 on pulse pressure (P=1.58×10 −8 ). The 2 df tests confirmed the ARL15 rs16882447 signal for systolic BP (P=1.15×10 −9 ). Genome-wide genebased analysis identified CC2D2A (P=2.59×10 −7 ) at 4p15.32 and BNC2 (P=4.49×10 −10 ) at 9p22.2 for systolic BP, GGNBP1 (P=1.18×10 −8 ), and LINC00336 (P=1.36×10 
Study Population
GenSalt is a family-based dietary intervention study designed to identify genes that influence BP responses to environmental risk factors for hypertension in human populations. The study includes 1906 Han Chinese participants aged ≥16 years from 633 families recruited from 6 study sites in rural, north China. 16 In the current study, genotypes, BP, and covariates at baseline are available for a total of 1876 participants (98.4%).
Institutional review boards at the Tulane University Health Sciences Center, Washington University School of Medicine, University of Texas School of Public Health, Fu Wai Hospital and Chinese National Human Genome Center at Beijing, and Chinese Academy of Medical Sciences approved the GenSalt study. Written informed consents for the baseline observation were obtained from each participant.
Genotyping and Genotype Imputation
A total of 868 158 autosomal SNPs across the entire genome were genotyped using the Affymetrix 6.0 platform for each participant. After excluding monomorphic SNPs and SNPs with HardyWeinberg equilibrium P<1×10 −6 , missing rate >25%, or minor allele frequency<1%, a total of 820 017 genotyped SNPs remained for genotype imputation. Imputation of 2 416 663 SNPs from the HapMap release 22 build 36 Chinese Han of Beijing and Japanese of Tokyo (CHB+JPT) reference panel was conducted using MACH software (version 1.0). 17 After imputation, SNPs with r 2 <0.30, minor allele frequency<1%, or Hardy-Weinberg equilibrium P<1×10 −6 were removed, and a total of 2 216 774 SNPs, with fractional values ranging from 0 to 2, remained for the analysis.
Urinary Potassium and Covariates Measurement
Dietary potassium intake was measured from 24-hour urinary potassium level. During the 3-day baseline examination, each GenSalt participant collected 3 urine samples, one 24-hour urine sample and 2 overnight urine samples. Among a random sample of 238 participants, 24-hour urine samples were collected in 2 containers, one for day time and the other for overnight. Using this random sample, an equation was generated to estimate 24-hour urinary potassium level from the overnight urine sample, and this equation was applied to the remaining overnight urine samples to estimate 24-hour urinary potassium levels. The mean of the 1 measured 24-hour urinary potassium level and 2 estimated 24-hour urinary potassium levels was used in the current analysis.
Demographic variables, including age and sex and medication use were collected using standard questionnaires by trained study staff. Body weight and height were measured twice during the baseline examination with the participants in light indoor clothing without shoes. Body mass index was calculated as kilograms per meters squared.
BP Measurement and Imputation
SBP, DBP, MAP, and PP phenotypes were assessed as outcomes in the current analyses. BP was measured 3 times at the same time each morning during the 3-day baseline examination by trained and certified observers using a random-zero sphygmomanometer according to standard protocol. For participants taking antihypertensive medications, BP was imputed by adding 10 mm Hg to SBP and 5 mm Hg to DBP. 18 After imputation, the mean of the 9 SBP and DBP measures were used in the current analysis. The mean SBP and DBP values were also used to calculate PP (SBP-DBP) and MAP (SBP/3+2*DBP/3) phenotypes.
Replication Study and Genotype Imputation
We attempted to replicate promising GenSalt findings (P<1×10 −4 ) among Chinese participants of the MESA (Multi-Ethnic Study of Atherosclerosis). MESA participants were recruited between July 2000 and August 2002 from 6 field centers around the United States. Participants were aged 45 to 84 and free of cardiovascular diseases at the baseline examination. Phenotype and Affymetrix 6.0 genotype data of MESA participants were made publicly available through the NCBI's database of Genotypes and Phenotypes (dbGaP) and were downloaded for the current analysis. Among 777 Chinese MESA participants, genotype, urinary potassium, BP, and all covariables at baseline were available for 775 participants (99.7%). Similar to GenSalt, we imputed BP for participants taking antihypertensive medication by adding 10 and 5 mm Hg to SBP and DBP, respectively. Because potassium was measured from spot urine using baseline urine samples, 24-hour urine potassium was estimated from spot urine potassium levels using Tanaka equation. 19 A total of 909 622 autosomal SNPs across the entire genome were genotyped using the Affymetrix 6.0 platform for each participant. We excluded SNPs with Hardy-Weinberg equilibrium P<1×10 −6 , missing rate >5%, and minor allele frequency<1%. Minimac software 20 was used to perform targeted imputation of the 3 Mb region surrounding each identified SNP based on the ALL ancestry panel from the 1000G Phase I Integrated Release Version 3 Haplotypes, which contains haplotypes of 1092 individuals of all ethnic background. 21 After imputation, SNPs with r 2 <0.30, minor allele frequency<1%, or Hardy-Weinberg equilibrium P<1×10 −6 were removed.
Statistical Analysis
To accommodate familial relationships in both GenSalt (discovery) and MESA (replication) studies, linear mixed-effect models were used to examine SNP-potassium interactions on BP, after adjustment for age, sex, and body mass index. Principal components analysis revealed population substructure in MESA (but not GenSalt). Therefore, ancestry was also accounted for in MESA by adjusting for the first 3 principal components. Both 1 df interaction and 2 df joint tests were explored. The 2 df joint test has higher power to identify variants with both moderate main effect and moderate interaction effect. 22 As shown in Figures I through IV in the Data Supplement, genomic inflation was minimal with λ values ranging from 1.029 for DBP in the 1 df interaction analyses to 1.075 for PP in the 2 df joint tests. Still, genomic control was applied to single SNP-based analyses results before gene-based analyses and metaanalyses. After genomic control, lead SNPs with interaction term P<1.0×10 −4 or joint test P<1.0×10 −4 from independent loci in the discovery stage analyses were further evaluated for replication in Chinese MESA participants. For the 1 df interaction test, inversevariance-weighted meta-analysis was conducted to combine results from GenSalt and MESA using METAL software. 23 For the 2 df joint test, meta-analysis was performed using methods described by Manning et al, 24 which were implemented in METAL software 23 with their patch source code. After ensuring that the effect direction of interaction terms were consistent, SNPs with replication stage P<0.05 and meta-analysis P<5.0×10 −8 were considered significant for the 1 df interaction test. SNPs with consistent effect directions in the main effect and interaction term, replication stage P<0.05, and joint meta-analysis P<5.0×10 −8 were considered significant for the 2 df joint test. We also conducted a sensitivity analysis restricting the replication study to Chinese MESA participants not taking any antihypertensive medication.
For the gene-based analyses, SNPs within the 5 kbp flanking regions of a gene were first mapped to the gene according to physical positions. SNPs within 5 kbp flanking regions of 2 genes were assigned to both genes. P values of both 1 df interaction and 2 df joint tests in single-marker analyses were used to generate gene-based P values using the extended Simes procedure (GATES) method for gene-based association testing. 10 Genes with P<1.0×10 −4 in the discovery stage gene-based interaction analysis were further evaluated for replication among Chinese MESA participants. Specifically, SNPs from promising genes were tested for SNP-potassium interactions using the methods described in the above single-marker analysis, and P values of these SNPs were used to generate genebased P values using GATES method. 10 Fisher method was applied Genome-Wide Gene-K Interaction Analyses on BP to combine gene-based P values across GenSalt and MESA. 25 Genes with replication stage P<0.05 and combined P<5.0×10 −6 were considered significant. Gene-based analysis combines contributions of all variants within a gene and, therefore, has higher power to detect genes interacting with dietary potassium intake on BP regulation compared with single-marker analyses.
Results
As shown in Table 1 , participants of both GenSalt and the MESA replication sample had, on average, optimal BP and body mass index levels. However, the Chinese MESA participants were older, had a higher proportion with hypertension, and had relatively higher potassium intake.
Two novel loci that achieved genome-wide significance in the combined analyses using the 1 df interaction test are presented in Table 2 and Figures IX through XII in the Data Supplement. Novel ARL15 gene variant rs16882447 interacted with potassium on SBP (GenSalt P=1.99×10 −7 , MESA P=2.28×10 −3 , and meta-analysis P=2.83×10 −9 ). In addition, significant gene-potassium interaction on PP was identified for RANBP3L gene variant rs958929 (GenSalt P=1.79×10 −7 , MESA P=1.66×10 −2 , and meta-analysis P=1.58×10 −8 ). Variant rs16882447 was also identified in the 2 df joint test (GenSalt P=9.79×10 −9 , MESA P=8.19×10 −3 , and meta-analysis P=1.15×10 −9 ) as shown in Table 3 . Regional association plots for the 2 novel loci achieving genome-wide significance in meta-analyses are presented in Figure. Results of sensitivity analyses conducted among Chinese MESA participants not taking antihypertension medication were similar to those conducted among the overall replication sample ( Table I in Table 4 . In the gene-based analysis of the 1 df test, significant interactions between potassium and the BNC2 and CC2D2A genes on SBP, GGNBP1 and LINC00336 on DBP, BNC2 gene on MAP, and DAB1 and MIR4466 on PP were identified. Gene-based analysis of the 2 df joint test confirmed the gene-BP associations for BNC2, CC2D2A, GGNBP1, and DAB1 genes and additionally identified novel gene-potassium interactions for RANBP3L on PP.
Discussion
In the first-ever genome-wide gene-potassium interaction study in a Chinese population, we identified 1 novel locus, ARL15, that interacted with potassium to influence the BP phenotypes using both the 1 df interaction test and 2 df joint test. The 1 df interaction test also provide direct evidence of a previously reported BP locus at RANBP3L. Furthermore, gene-based analyses using both the 1 df and 2 df joint tests revealed 6 additional genes at 5 novel loci that were associated with BP, including CC2D2A at 4p15.32 and BNC2 at 9p22.2 for SBP, GGNBP1 and LINC00336 at 6p21 for DBP, DAB1 at 1p32.2, and MIR4466 at 6q25.3 for PP. BNC2 gene was also significant for MAP. These findings contribute to our understanding of the biological mechanisms underlying BP regulation.
Novel ARL15 marker rs16882447 was identified by both the 1 df interaction test and the 2 df joint test. The 2 df joint test signal was mainly driven by the interaction effect. The ARL15 gene encodes ADP ribosylation factor like GTPase 15. 26 This gene has been previously identified by genome-wide association studies of related cardiometabolic traits including diabetes mellitus, 27 rheumatoid arthritis, 28 high-density lipoprotein cholesterol, 29 and adiponectin. 30 More importantly, a recent genome-wide association study by Gorski et al 31 identified that the ARL15 gene was associated with kidney function. Considering the importance of kidney function in BP regulation and potassium filtration, further investigation into this gene is warranted. Although the functional relevance of ARL15 to BP is unclear, this signal could reflect other genes at this locus. For example, the nearby HSPB3 gene, encoding the heat shock protein family B (small) member 3, 32 represents a biologically plausible candidate for hypertension. The HSPB3 gene is highly expressed in heart and skeletal muscles. 33 Animal studies showed that cardiac overloading related to hypertension increased expression of the Hspb3 gene in rat models. 34 Furthermore, in Bnp knockout rats, Hspb3 was overexpressed in hypertrophic left ventricular mass before the development of adult-onset hypertension. 35 Future studies with higher genotyping resolution at this locus are warranted to identify the causal variant(s) that interact with potassium intake on hypertension.
The 1 df test also provided the first robust evidence for the relevance of the RANBP3L locus in BP regulation. A previous study using a 2-marker association testing approach identified a SNP pair ≈200 kb downstream from RANBP3L for hypertension. 36 However, the study did not replicate their association signals in an independent sample. Our study identified a significant interaction between intronic RANBP3L variant rs958929 and dietary potassium intake on PP, which was replicated among MESA findings. Three variants in the RANBP3L gene were positively associated with urinary potassium levels BMI indicates body mass index; DBP, diastolic blood pressure; and SBP, systolic blood pressure. Genome-Wide Gene-K Interaction Analyses on BP (Table II in the Data Supplement). Therefore, the involvement of this gene in BP regulation may be mediated through its role in potassium metabolism. Our finding is further supported by a recent functional study, in which extracellular osmolality within the renal medulla upregulated the expression of RanBP3L. 37 The RANBP3L signal may have also reflect other genes in this locus. For example, a nearby gene, SKP2 encoding S-phase kinase associated protein 2, interacts with p27 and promotes p27 degradation. 38 Skp2 knockout mice showed p27 accumulation in cells 38, 39 and subsequently inhibited renal tubular epithelial cell proliferation and reduced renal damage. 40 Considering the importance of kidney function in BP regulation and potassium filtration, this locus warrants further investigation.
Gene-based analysis of the 1 df interaction test and 2 df joint test identified 6 additional genes (DAB1, CC2D2A, GGNBP1, LINC00336, MIR4466, and BNC2) at 5 novel loci that were associated with BP. The 6 genes were not reported in previous genome-wide association studies of cardiovascular related phenotypes. However, the GGNBP1 gene was previously reported to associate with SBP in a secondary analysis using the genetic pleiotropy-informed conditional false-discovery rate method. 41 In addition, mutations in the CC2D2A gene have been shown to cause Joubert syndrome, a disorder characterized by renal impairment and hypertension. 42 The functional relevance of the other identified genes on BP regulation is unclear. Future studies of these genes are warranted.
Our study has several strengths. First of all, stringent quality control measures were used for genotyping, data cleaning, covariable collection, BP measurement, and urinary potassium measurement. Second, because we limited our analysis to Chinese participants, population stratification should be minimized. Third, GenSalt was a family-based study, and dietary potassium intake should have strong familial resemblance; therefore, 24-hour urinary potassium levels should have smaller variability, and subsequently, we should have stronger statistical power to test gene-potassium interactions on BP. Finally, a total of 9 BP were measured using random-zero sphygmomanometer at the same time during the 3-day baseline examination in GenSalt. Using multiple BP measures should greatly reduce measurement error and increase statistical power to detect genetic variants for BP. However, certain limitations should also be addressed. The Chinese MESA replication sample was small, and we may not have had enough power to replicate all promising findings from the GenSalt study. In addition, 24-hour potassium level was estimated from spot urine using Tanaka equation in MESA. Although the method has been validated previously, any measurement error could further reduce statistical power for replicating genetic variants identified in GenSalt. In addition, MESA had a high proportion of participants taking antihypertensive medication. We imputed BP by adding 10 and 5 mm Hg to SBP and DBP, respectively. Although this approach is widely applied to genetic studies of BP, 2, 3, 5 any resulting inaccuracy may dilute associations between genetic factors and BP. Furthermore, additional factors such as age and urbanization level differ between the GenSalt and MESA samples. If these factors influence gene-potassium interactions on BP, our power to detect (or replicate) SNP-BP associations could again be reduced. Imputation quality of the significant SNPs in MESA was not high. Thus, future replication studies with larger replication sample sizes, more homogeneous populations, better measurement of urinary potassium levels, and higher imputation quality or higher genotyping resolution are warranted. Finally, GenSalt study did not collect data on serum potassium level, so we cannot assess correlations between daily potassium intake and serum potassium levels.
In conclusion, in the first-ever genome-wide gene-potassium interaction analyses of BP in a Chinese population, using both single-marker and gene-based analyses, we identified 6 novel loci that interacted with dietary potassium intake on SBP and provided first robust evidence of the relevance of the RANBP3L locus in BP regulation. Both 1 df interaction and 2 df joint tests of single markers identified novel locus ARL15 rs16882447. Gene-based analyses provided consistent support for the RANBP3L gene and identified an additional 6 genes at 5 novel loci, including DAB1, CC2D2A, MIR4466, GGNBP1, LINC00336, and BNC2. Such findings highlight the importance of examining gene-potassium interactions and conducting gene-based analysis to identify novel BP loci. Further, these findings contribute to understanding the mechanisms of BP regulation. Sequencing along with functional studies are needed to help delineate causal variants underlying the strong signals identified here.
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